1.
Pincez T, Bruneau J, Berteloot L, Piekarski E, Thomas C, Marçais A, Trinquand A, Castelle M, Garcelon N, Plantaz D, Cheminant M, Moshous D, Molina TJ, Hermine O, Macintyre E, Fischer A, Blanche S, Suarez F, Neven B. Safety and efficacy of brentuximab vedotin as a treatment for lymphoproliferative disorders in primary immunodeficiencies. haematol [Internet]. 2020Jun.5 [cited 2024Mar.3];105(9):e461-e464. Available from: https://haematologica.org/article/view/9870